Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Hormone shifts during menstruation, pregnancy, and menopause can trigger depression in susceptible women, highlighting connected brain pathways and guiding targeted, stabilizing treatments.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.